NCT05419479 2026-02-24
Switch Maintenance in Pancreatic
Dana-Farber Cancer Institute
Phase 1/2 Suspended
Clinical Trials
13 trialsNCT03065062 2026-02-13
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Suspended
NCT05494697 2025-10-14
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
AIM ImmunoTech Inc.
Phase 2 Suspended
NCT03417921 2025-10-01
Pancreatic
Ability Pharmaceuticals SL
Phase 1/2 Suspended
NCT05958199 2025-06-27
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NextPoint Therapeutics, Inc.
Phase 1 Suspended
NCT03711890 2025-03-30
Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer
Ohio State University Comprehensive Cancer Center
Phase NA Suspended
NCT04090463 2024-05-07
PancFORT
Universita di Verona
Phase 2 Suspended
NCT03610100 2019-10-29
ACELARATE
The Clatterbridge Cancer Centre NHS Foundation Trust
Phase 2/3 Suspended
NCT01330823 2011-04-07
CARPAN
University Medicine Greifswald
Phase 3 Suspended
NCT00909558 2010-02-24
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
Envita Medical Center, Inc.
Phase 1 Suspended
NCT00637364 2009-01-13
HIFU Pancreas
CMED HIFU Development Corporation
Phase 1/2 Suspended
NCT00536770 2007-11-06
A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer
Novacea
Phase 2 Suspended
NCT00209677 2007-11-01
Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Hokkaido Gastrointestinal Cancer Study Group
Phase 1/2 Suspended